Study of Leukocyte Populations in Patients With Chronic Inflammatory (LIMA)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04749875 |
Recruitment Status :
Not yet recruiting
First Posted : February 11, 2021
Last Update Posted : February 11, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Systemic Autoimmune Disease Chronic Inflammatory Rheumatism Sjogren's Syndrome Spondyloarthritis Rheumatoid Arthritis Systemic Lupus Erythematosus | Other: blood sample |
Study Type : | Observational |
Estimated Enrollment : | 1500 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Study of Leukocyte Populations in Patients With Chronic Inflammatory |
Estimated Study Start Date : | March 1, 2021 |
Estimated Primary Completion Date : | March 1, 2026 |
Estimated Study Completion Date : | March 1, 2026 |
- Other: blood sample
sampling of blood for research during routine care
- Characterization of the quantitative and qualitative specificities of the different leukocyte subpopulations in patients with chronic inflammatory rheumatism and rare systemic autoimmune diseases [ Time Frame: At the end of the study (5 years) ]Proportion of different leukocytes subset
- Protein study (ELISA on serum) : IL7 [ Time Frame: At the end of the study (5 years) ]levels of IL7 and other cytokines
- Transcriptome study (RNA) : mRNA levels [ Time Frame: At the end of the study (5 years) ]assessement of different mRRNA involved in Il7/IFN pathways by molecular biology techniques (RNAseq, qPCR, nano string)
- Genomic study (DNA) : SNPs [ Time Frame: At the end of the study (5 years) ]Determination of the genotype of different SNPs involved in IL7/IFN pathways
Biospecimen Retention: Samples Without DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Age ≥18 years
- Patient who did not express his opposition
- Patients with chronic inflammatory rheumatism and rare systemic autoimmune diseases (pSS, lupus, scleroderma, myositis, unclassified connectivitis) diagnosed according to the usual criteria.
- Weight> 35 kg
Exclusion Criteria:
- Corticosteroid treatment> 10 mg / day
- Pregnant patient
- Patients under legal protection
- Beneficiary of the state medical aid
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04749875
Contact: Xavier MARIETTE | 00 33 1 45 21 37 58 | xavier.mariette@aphp.fr |
France | |
CHU Bicêtre | |
Le Kremlin-Bicêtre, France, 94275 | |
Contact: Xavier Mariette, MD, PhD +33 (0)1 45 21 37 51 xavier.mariette@bct.aphp.fr | |
Contact: Gaetane Nocturne, MCU-PH 0033 1 45 21 37 57 gaetane.nocturne@aphp.fr | |
Principal Investigator: Xavier Mariette, MD, PhD |
Principal Investigator: | Gaetane Nocturne | APHP |
Responsible Party: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT04749875 |
Other Study ID Numbers: |
APHP210093 |
First Posted: | February 11, 2021 Key Record Dates |
Last Update Posted: | February 11, 2021 |
Last Verified: | February 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
leukocytes macrophages lymphocytes rare systemic autoimmune diseases chronic inflammatory rheumatism |
Rheumatic Fever Sjogren's Syndrome Rheumatic Diseases Lupus Erythematosus, Systemic Collagen Diseases Autoimmune Diseases Arthritis Joint Diseases Musculoskeletal Diseases Arthritis, Rheumatoid Connective Tissue Diseases Immune System Diseases |
Xerostomia Salivary Gland Diseases Mouth Diseases Stomatognathic Diseases Dry Eye Syndromes Lacrimal Apparatus Diseases Eye Diseases Infections Streptococcal Infections Gram-Positive Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses |